Vericel (NASDAQ:VCEL) Issues Earnings Results

Vericel (NASDAQ:VCEL) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21, Zacks reports. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same quarter in the prior year, the firm earned $0.10 EPS. The company’s revenue was up 26.5% on a year-over-year basis.

Here are the key takeaways from Vericel’s conference call:

• Vericel reported third-quarter revenue of $85.4 million, up 26%, and raised 2026 revenue guidance to $344 million–$346 million after results exceeded expectations. The company also raised adjusted EBITDA margin guidance to approximately 28%.
• MACI revenue grew 21% to a record $67.4 million, with records for biopsies, implants, and participating surgeons; October also brought the strongest biopsy month since launch. Management cited sales-force expansion, deeper surgeon engagement, and MACI Arthro adoption as growth drivers, while noting that biopsies convert to procedures over time.
• Burn-care revenue reached a record $18 million, up 52%, with record quarterly revenue for both Epicel and commercial NexoBrid. Management attributed Epicel’s strength mainly to commercial execution, while acknowledging that burn-care results can be variable and that the number of severe burns is outside the company’s control.
• Profitability and cash generation strengthened: adjusted EBITDA rose 48% to $25.2 million, free cash flow was $16 million, and the company ended the quarter with $236 million in cash and investments and no debt. Vericel said it remains on track with its longer-term targets, while continuing investments in growth and exploring both share repurchases and business development.

Vericel Stock Performance

Shares of VCEL stock opened at $51.78 on Friday. Vericel has a 52-week low of $28.95 and a 52-week high of $55.60. The stock has a market cap of $2.65 billion, a PE ratio of 110.17 and a beta of 1.08. The firm’s 50 day moving average price is $40.74 and its two-hundred day moving average price is $38.80.

Vericel News Summary

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while net income increased 179% to $14.2 million. EPS of $0.27 also beat analyst expectations, as did revenue of $85.4 million versus estimates of about $78 million. Vericel third-quarter results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344 million–$346 million, above the roughly $336 million consensus estimate, and forecast a 28% adjusted EBITDA margin. The higher outlook signals continued business momentum. Vericel raises FY2026 outlook
• Positive Sentiment: Coverage highlighted record sales of MACI, Vericel’s cartilage repair product, as a key driver of results and the raised outlook. Vericel record revenue and raised outlook
• Negative Sentiment: A separate analysis characterized VCEL as potentially overvalued relative to its earnings support. That valuation concern could temper investor enthusiasm after the strong results, although the provided article details do not quantify its valuation case. Vericel valuation analysis

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on VCEL shares. Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a research report on Thursday, July 30th. TD Cowen boosted their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Truist Financial decreased their price objective on Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, October 14th. Finally, HC Wainwright increased their price objective on Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Friday. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.20.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.